Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
The development of the dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar as an oral antidiabetic was recently discontinued. Here we present tumor data from a 2-year carcinogenicity study in rats given 0.3, 1, 3, and 10 micromol/kg tesaglitazar is presented with focus on the findings of subcutaneous fibrosarcomas. To investigate the mechanism for induction of fibrosarcomas, replicative DNA synthesis (immunohistochemical detection of BrdU-labeled cells) and expression of PPARgamma (immunohistochemistry and reverse transcription-polymerase chain reaction) in subcutaneous adipose tissues was assessed in rats administered 1 or 10 micromol/kg for 2 weeks or 3 months. Poorly differentiated subcutaneous mesenchymal sarcomas with a predominant spindle cell appearance occurred at the highest dose level of 10 micromol/kg in both sexes, and these tumors were diagnosed as fibrosarcomas. The 10-micromol/kg dose was at or above the maximum tolerated dose and caused considerable cardiovascular mortality. Tesaglitazar stimulated DNA synthesis mainly in subcutaneous interstitial mesenchymal cells. The percentage of BrdU-labeled interstitial cells was increased at 1 and 10 micromol/kg after 2 weeks. The increase in DNA synthesis was still significant at the end of the 12-week treatment at 10 mumol/kg, the dose producing fibrosarcoma. However, at 1 micromol/kg, a dose below the no-observed-effect level for fibrosarcoma, the level of DNA synthesis was similar to control levels at 12 weeks. Immunohistochemical analyses showed no detectable PPARgamma protein in the majority of BrdU-labeled interstitial mesenchymal cells in white and brown fat. This indicates that stimulation of DNA synthesis is not mediated via direct activation of PPARgamma in these cells. The results suggest that the induction of rat fibrosarcoma by tesaglitazar, at exposures 100-fold above the human therapeutic exposure, may involve proliferation of undifferentiated mesenchymal cells in subcutaneous tissues.
Hellmold
Heike
H
Department of Safety Assessment, AstraZeneca R&D Södertälje, Södertälje, Sweden. heike.hellmold@astrazeneca.com
Zhang
Hui
H
Andersson
Ulf
U
Blomgren
Bo
B
Holland
Tom
T
Berg
Anna-Lena
AL
Elebring
Marie
M
Sjögren
Niclas
N
Bamberg
Krister
K
Dahl
Björn
B
Westerberg
Rolf
R
Dillner
Birgitta
B
Tugwood
Jonathan
J
Tugwood
Jonathan
J
Roberts
Ruth
R
Lundholm
Erik
E
Camejo
German
G
Skånberg
Inger
I
Evans
John
J
D000476:Alkanesulfonates / Q000494:pharmacology*; D000818:Animals; D000963:Antimetabolites; D001973:Bromodeoxyuridine; D002784:Cholesterol / Q000097:blood; D004247:DNA / Q000096:biosynthesis*; D004261:DNA Replication / Q000187:drug effects; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced* / Q000473:pathology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D008648:Mesoderm / Q000187:drug effects / Q000378:metabolism*; D042282:Microdissection; D009929:Organ Size / Q000187:drug effects; D047493:PPAR alpha / Q000819:agonists*; D047495:PPAR gamma / Q000819:agonists*; D010666:Phenylpropionates / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D012313:RNA / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D014280:Triglycerides / Q000097:blood
D000476:Alkanesulfonates; D000963:Antimetabolites; D007004:Hypoglycemic Agents; D047493:PPAR alpha; D047495:PPAR gamma; D010666:Phenylpropionates; D014280:Triglycerides; D012313:RNA; C501413:tesaglitazar; D004247:DNA; D002784:Cholesterol; D001973:Bromodeoxyuridine